loader

asx:rad

LATEST ARTICLES
Participation in B Riley Securities Radiopharma Conference

Participation in B Riley Securities Radiopharma Conference

Clinical trial data shows RAD 101 detects Brain Metastases

Clinical trial data shows RAD 101 detects Brain Metastases

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Lantheus increases shareholding in RAD with A$8m placement

Lantheus increases shareholding in RAD with A$8m placement

Strategic Co-Development Partnership with Lantheus for Aus

Strategic Co-Development Partnership with Lantheus for Aus

RAD 202 receives approval to start Phase 1 therapeutic trial

RAD 202 receives approval to start Phase 1 therapeutic trial

Completion of preclinical data package for RAD 402

Completion of preclinical data package for RAD 402

Radiopharm achieves Nasdaq listing of ADS

Radiopharm achieves Nasdaq listing of ADS

Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD)

Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing Nears

Radiopharm Theranostics

68Ga-RAD 301 (68Ga-Trivehexin) Demonstrates Strong Potential for Imaging of αvβ6-Integrin Expression in Pancreatic Cancer Patients

Radiopharm Theranostics

Quarterly Activities & Cash Report and 4C for the Quarter ended 30 September 2024

Latest News

More News